RET (V804M)-KIF5B
Sign in to save this workspaceKIF5B-RET · Variant type: fusion · HGVS: p.Fusion;p.V804M · Fusion partner: KIF5B (V804M)
Components
p.Fusionp.V804M
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 99.4% | 0.6% | 93.43 |
| 2 | Tenalisib | 98.2% | 1.8% | 97.98 |
| 3 | Selpercatinib | 97.4% | 2.6% | 96.72 |
| 4 | Sunitinib | 97.4% | 2.6% | 91.73 |
| 5 | Alpelisib | 97.1% | 2.9% | 97.22 |
| 6 | Brigatinib | 96.4% | 3.6% | 82.96 |
| 7 | Dacomitinib | 96.2% | 3.8% | 97.99 |
| 8 | Entrectinib | 96.1% | 3.9% | 93.69 |
| 9 | Gilteritinib | 91.1% | 8.9% | 88.97 |
| 10 | Baricitinib | 89.2% | 10.8% | 97.99 |
| 11 | Fedratinib | 88.7% | 11.3% | 96.21 |
| 12 | Tivozanib | 88.3% | 11.7% | 92.42 |
| 13 | Fostamatinib | 87.4% | 12.6% | 96.74 |
| 14 | Defactinib | 86.9% | 13.1% | 92.68 |
| 15 | Futibatinib | 86.7% | 13.3% | 98.48 |
| 16 | Avapritinib | 70.1% | 29.9% | 97.73 |
| 17 | Repotrectinib | 60.8% | 39.2% | 84.21 |
| 18 | Deucravacitinib | 54.1% | 45.9% | 98.99 |
| 19 | Sorafenib | 50.7% | 49.3% | 96.72 |
| 20 | Upadacitinib | 49.7% | 50.3% | 97.98 |
| 21 | Lapatinib | 47.9% | 52.1% | 99.25 |
| 22 | Capivasertib | 41.2% | 58.8% | 96.48 |
| 23 | Ripretinib | 36.6% | 63.4% | 92.95 |
| 24 | Pazopanib | 36.2% | 63.8% | 97.49 |
| 25 | Quizartinib | 33.9% | 66.1% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 99.4% | — | — |
| Tenalisib | 98.2% | — | — |
| Selpercatinib | 97.4% | — | — |
| Sunitinib | 97.4% | — | — |
| Alpelisib | 97.1% | — | — |
| Brigatinib | 96.4% | — | — |
| Dacomitinib | 96.2% | — | — |
| Entrectinib | 96.1% | — | — |
| Gilteritinib | 91.1% | — | — |
| Baricitinib | 89.2% | — | — |
| Fedratinib | 88.7% | — | — |
| Tivozanib | 88.3% | — | — |
| Fostamatinib | 87.4% | — | — |
| Defactinib | 86.9% | — | — |
| Futibatinib | 86.7% | — | — |
| Avapritinib | 70.1% | — | — |
| Repotrectinib | 60.8% | — | — |
| Deucravacitinib | 54.1% | — | — |
| Sorafenib | 50.7% | — | — |
| Upadacitinib | 49.7% | — | — |
| Lapatinib | 47.9% | — | — |
| Capivasertib | 41.2% | — | — |
| Ripretinib | 36.6% | — | — |
| Pazopanib | 36.2% | — | — |
| Quizartinib | 33.9% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.9ms